Abstract:Background Remarkable advances for clinical diagnosis and treatment in cancers including lung cancer involve cell-free circulating tumor DNA (ctDNA) detection through next generation sequencing. However, before the sensitivity and specificity of ctDNA detection can be widely recognized, the consistency of mutations in tumor tissue and ctDNA should be evaluated. The urgency of this consistency is extremely obvious in lung cancer to which great attention has been paid to in liquid biopsy field. Methods We have developed an approach named systematic error correction sequencing (Sec-Seq) to improve the evaluation of sequence alterations in circulating cell-free DNA. Averagely 10 ml preoperative blood samples were collected from 30 patients containing pulmonary space occupying pathological changes by traditional clinic diagnosis. cfDNA from plasma, genomic DNA from white blood cells, and genomic DNA from solid tumor of above patients were extracted and constructed as libraries for each sample before subjected to sequencing by a panel contains 50 cancer-associated genes encompassing 29 kb by custom probe hybridization capture with average depth >40000, 7000, or 6300 folds respectively. Results Detection limit for mutant allele frequency in our study was 0.1%. The sequencing results were analyzed by bioinformatic expertise based on our previous studies on the baseline mutation profiling of circulating cell-free DNA and the clinicopathological data of these patients. Among all the lung cancer patients, 78% patients were predicted as positive by ctDNA sequencing when the shreshold was defined as at least one of the hotspot mutations detected in the blood (ctDNA) was also detected in tumor tissue. Pneumonia and pulmonary tuberculosis were detected as negative according to the above standard. When evaluating all hotspots in driver genes in the panel, 24% mutations detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). When evaluating all genetic variations in the panel, including all the driver genes and passenger genes, 28% detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). Positive detection rates of plasma ctDNA in stage I lung cancer patients is 85%, compared with 17% of tumor biomarkers. Conclusion We demonstrated the importance of sequencing both circulating cell-free DNA and genomic DNA in tumor tissue for ctDNA detection in lung cancer currently. We also determined and confirmed the consistency of ctDNA and tumor tissue through NGS according to the criteria explored in our studies. Our strategy can initially distinguish the lung cancer from benign lesions of lung. Our work shows that the consistency will be benefited from the optimization in sensitivity and specificity in ctDNA detection.

Liquid Biopsy-Based Accurate Diagnosis and Genomic Profiling of Hard-to-Biopsy Tumors via Parallel Single-Cell Genomic Sequencing of Exfoliated Tumor Cells

Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis

The functional and clinical roles of liquid biopsy in patient-derived models

A high-throughput liquid biopsy for rapid rare cell separation from large-volume samples

Liquid Biopsy, ctDNA Diagnosis through NGS

Liquid Biopsy Instrument for Ultra-Fast and Label-Free Detection of Circulating Tumor Cells

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer

Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

Liquid biopsy: current technology and clinical applications

Non-invasive Lung Cancer Diagnosis and Prognosis Based on Multi-Analyte Liquid Biopsy.

Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma

Liquid Biopsy for Early Diagnosis of Hepatocellular Carcinoma: Current State and Future Perspectives

Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer

The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

Cell-free DNA from Bile Outperformed Plasma As a Potential Alternative to Tissue Biopsy in Biliary Tract Cancer

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Liquid biopsy epigenomic profiling for cancer subtyping

Biosynthesis of RNA in Two Nuclear Classes Separated from Rat Cerebral Cortex

Liquid biopsy: paving a new avenue for cancer research